Kotschade L.A. et al. (2011) published the results of a phase II clinical trial (NCT00404235) that included patients diagnosed with unresectable stage IV melanoma who received a combined treatment with nanoparticle albumin-bound–paclitaxel and carboplatin [83]. The gene discussed is ALB; the disease is melanoma.